U.S. markets closed
  • S&P 500

    4,448.98
    +53.34 (+1.21%)
     
  • Dow 30

    34,764.82
    +506.50 (+1.48%)
     
  • Nasdaq

    15,052.24
    +155.40 (+1.04%)
     
  • Russell 2000

    2,259.04
    +40.48 (+1.82%)
     
  • Crude Oil

    73.24
    +1.01 (+1.40%)
     
  • Gold

    1,742.80
    -36.00 (-2.02%)
     
  • Silver

    22.52
    -0.39 (-1.69%)
     
  • EUR/USD

    1.1743
    +0.0047 (+0.40%)
     
  • 10-Yr Bond

    1.4100
    +0.0740 (+5.54%)
     
  • GBP/USD

    1.3724
    +0.0104 (+0.76%)
     
  • USD/JPY

    110.2960
    +0.5180 (+0.47%)
     
  • BTC-USD

    44,696.22
    +1,168.09 (+2.68%)
     
  • CMC Crypto 200

    1,119.18
    +10.26 (+0.92%)
     
  • FTSE 100

    7,078.35
    -5.02 (-0.07%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

Top Ranked Value Stocks to Buy for December 21st

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Here are three stocks with buy rank and strong value characteristics for investors to consider today, December 21st:

Mallinckrodt plc (MNKKQ): This developer and manufacturer of specialty pharmaceutical products and therapies has a Zacks Rank #1 (Strong Buy), and seen the Zacks Consensus Estimate for its current year earnings rising 13.7% over the last 60 days.

Mallinckrodt public limited company Price and Consensus

Mallinckrodt public limited company Price and Consensus
Mallinckrodt public limited company Price and Consensus

Mallinckrodt public limited company price-consensus-chart | Mallinckrodt public limited company Quote

Mallinckrodt has a price-to-earnings ratio (P/E) of 0.06 compared with 0.20 for the industry. The company possesses a Value Score of A.

Mallinckrodt public limited company PE Ratio (TTM)

Mallinckrodt public limited company PE Ratio (TTM)
Mallinckrodt public limited company PE Ratio (TTM)

Mallinckrodt public limited company pe-ratio-ttm | Mallinckrodt public limited company Quote

Danaos Corporation (DAC): This owner and operator of containerships in Australia, Asia, Europe, and the United States has a Zacks Rank #1, and seen the Zacks Consensus Estimate for its current year earnings rising 1.6% over the last 60 days.

Danaos Corporation Price and Consensus

Danaos Corporation Price and Consensus
Danaos Corporation Price and Consensus

Danaos Corporation price-consensus-chart | Danaos Corporation Quote

Danaos has a price-to-earnings ratio (P/E) of 2.85 compared with 9.70 for the industry. The company possesses a Value Score of A.

Danaos Corporation PE Ratio (TTM)

Danaos Corporation PE Ratio (TTM)
Danaos Corporation PE Ratio (TTM)

Danaos Corporation pe-ratio-ttm | Danaos Corporation Quote

Elevate Credit, Inc. (ELVT): This provider of online credit solutions to non-prime consumers in the United States and the United Kingdom has Zacks Rank #2 (Buy), and seen the Zacks Consensus Estimate for its current year earnings rising 25% over the last 60 days.

Elevate Credit, Inc. Price and Consensus

Elevate Credit, Inc. Price and Consensus
Elevate Credit, Inc. Price and Consensus

Elevate Credit, Inc. price-consensus-chart | Elevate Credit, Inc. Quote

Elevate Credit has a price-to-earnings ratio (P/E) of 3.04 compared with 12.90 for the industry. The company possesses a Value Score of A.

Elevate Credit, Inc. PE Ratio (TTM)

Elevate Credit, Inc. PE Ratio (TTM)
Elevate Credit, Inc. PE Ratio (TTM)

Elevate Credit, Inc. pe-ratio-ttm | Elevate Credit, Inc. Quote

See the full list of top ranked stocks here

Learn more about the Value score and how it is calculated here.

Find more top income stocks with some of our great premium screens.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Mallinckrodt public limited company (MNKKQ) : Free Stock Analysis Report
 
Elevate Credit, Inc. (ELVT) : Free Stock Analysis Report
 
Danaos Corporation (DAC) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research